microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN

  • Authors:
    • Jian Hua Mao
    • Rong Ping Zhou
    • Ai Fen Peng
    • Zhi Li Liu
    • Shan Hu Huang
    • Xin Hua Long
    • Yong Shu
  • View Affiliations

  • Published online on: August 16, 2012     https://doi.org/10.3892/ol.2012.863
  • Pages: 1125-1129
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

microRNAs are involved in different cancer-related processes. miR-195, one of the miR-16/15/195/424/497 family members, has been shown to act as a tumor suppressor during tumorigenesis. However, the function of miR-195 in osteosarcoma is still unclear. In our study, the miR-195 expression level was upregulated in osteosarcoma cells, by transfection with miR-195, and the fatty acid synthase (FASN) mRNA and protein expression levels were measured by RT-PCR and western blotting. Cell migration and invasion was measured using wound healing migration and Transwell invasion assays. We found that the upregulation of miR-195 greatly decreased cell invasion and the migration of U2OS. We also identified that FASN may be a direct target of miR-195 by the luciferase activity assay. These findings provide evidence that miR-195 plays a key role in inhibiting osteosarcoma cell migration and invasion through targeting FASN, and strongly suggest that exogenous miR-195 may have therapeutic value in treating osteosarcoma.

Introduction

Osteosarcoma (OS) is the most common primary malignant neoplasm in adolescents. The estimated worldwide incidence rate is 4 million per year, with a peak incidence at the age of 15–19 years (1). By combining surgery with multiagent chemotherapy, the 5-year cumulative survival rate of primary OS has significantly improved to 60–90% in the past three decades (26). Unfortunately, as a result of approximately 80% of patients eventually developing metastatic disease following surgical treatment (7), pulmonary metastasis in OS patients is a major cause of fatal outcome (8). Therefore, it is essential to determine the mechanisms contributing to invasion and metastasis in OS.

Fatty acid metabolic pathways play an important role in carcinogenesis (9). Fatty acid synthase (FASN) is an enzyme crucial to endogenous lipogenesis in mammals and is responsible for catalyzing the synthesis of long-chain fatty acids. FASN is critical in sustaining the biological features of cancer cells (10). FASN is expressed at high levels in a variety of human tumors (1114), but exists at low levels in normal tissues. Various studies have reported that the inhibition of FASN expression suppresses cancer cell proliferation in vitro and in vivo (1520). Thus, FASN is considered a novel promising target for anticancer therapy. Recent studies (21,22) have revealed that FASN may also contribute to cancer cell metastasis.

microRNAs (miRNAs) are endogenous small RNAs averaging 20 to 24 nucleotides, transcribed from non-protein-coding genes or introns, which mediate translational suppression or cleavage of their target mRNAs by binding to complementary sites in their 3′-UTR (2325). A large number of miRNAs are located inside or close to chromosomal fragile sites that are frequently lost or amplified in cancers (26). miRNAs have been characterized as oncogenes, tumor suppressors or as components of regulatory pathways critical for tumorigenesis, therefore miRNAs play an important role in tumorigenesis and metastasis.

Recently, miR-195 has been reported to be deregulated in certain types of cancer, including upregulation in chronic lymphocytic leukemia and breast cancer but downregulation in hepatocellular carcinoma, adrenocortical carcinoma, and squamous cell carcinoma of the tongue (2731). miR-195 was also suggested to be correlated with lymph node metastasis and poor prognosis in colorectal cancer (27). However, the role of miR-195 in OS migration remains elusive. In our previous study, the prediction was performed by microRNA.org and TargetScan.human6.0. The results revealed that FASN may be a target of miR-195. Therefore, we speculate that miR-195 may suppress OS invasion and metastasis by targeting FASN.

In the present study, we found that miR-195 functions as a tumor suppressor in OS, upregulates miR-195 expression in the OS cell line U2OS and reduces cell migration and invasion in vitro. Additionally, it was revealed that FASN may be directly targeted by miR-195. Together, our data indicate that miR-195 plays an important role in regulating OS cell metastasis by targeting FASN.

Materials and methods

Cell culture and transfection

The human OS cell line U2OS (Shanghai Cell Bank, Chinese Academy of Sciences) was cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) and incubated at 37˚C in 5% CO2. U2OS cells were seeded in six-well plates at 30% confluence one day prior to transfection. Transfection with miR-195 or negative miRNA was performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). Transfection complexes were prepared according to the manufacturer’s instructions.

Quantitative real-time PCR (qRT-PCR)

Total RNA from cells treated with miR-195 or the negative control miRNA was isolated using a TRIzol reagent (Tiangen, Beijing, China) and reverse transcribed using a reverse transcription kit (Tiangen) according to the manufacturer’s instructions. Reactions were performed and analyzed using an ABI 7300 system (Applied Biosystems, Carlsbad, CA, USA). β-actin was used as the internal control to quantify initial cellular transcripts. Details of the primers and probes used in this study are summarized in Table I. All qRT-PCR were performed six times according to the manufacturer’s instructions. The relative expression level of FASN was normalized to that of β-actin by the 2ΔΔCt cycle threshold method. The ΔCt data were collected automatically. The average ΔCt of each group was calculated by the following formula: ΔCt = average miR-195 Ct - average of β-actin Ct. ΔΔCt was calculated by ΔΔCt = ΔCt of miR-195 group - ΔCt of the negative control group. The fold-change in FASN expression level was calculated using 2ΔΔCt.

Table I

Primers and probes.

Table I

Primers and probes.

Primers and probesSequences 5′-3′
FASN sense 5′-AAGCAGGCACACACGATGG-3′
FASN antisense 5′-TCGGAGTGAATCTGGGTTGATG-3′
FASN probe 5′-CTGCGGCTGCTGCTGGAAGTCACC-3′
β-actin sense 5′-TGCCCATCTACGAGGGGTATG-3′
β-actin antisense 5′-CTCCTTAATGTCACGCACGATTTC-3′
β-actin probe 5′-CCTGCGTCTGGACCTGGCTGGC-3′

[i] FASN, fatty acid synthase.

Luciferase activity assay

Primers were designed in accordance with the Genbank query FASN gene mRNA (NM_004104.4) sequence. A fragment of the 3′-UTR of FASN was amplified from U2OS cells by PCR using the forward primer 5′-CCCCTCGAGCCTGCCACCGGAGGTCACT-3′ and the reverse primer 5′-CGGGCGGCCGCGTGGGAG GCTGAGAGCAGCA-3′. Following digestion of the PCR product by XhoI and NotI, the FASN 3′-UTR was cloned into pSiCHECK2 (Promega, Madison, WI, USA) at the XhoI and NotI sites. All PCR products were verified by DNA sequencing. U2OS cells were cotransfected with the pSiCHECK2 vectors containing the 3′-UTR variants and miR-195 or the negative control miRNA. Luciferase activity was measured 36 h after transfection. The firefly luciferase activity was then normalized to the Renilla luciferase activity.

Transwell invasion assay in vitro

Invasion assays were performed in triplicate using Transwell invasion chambers (Costar 3422, Corning Inc., NY, USA) coated with Matrigel (50 μl per filter) (BD, USA) as described in the manufacturer’s instructions. U2OS cells were transfected with either miR-195 or the negative control oligonucleotide, cultured for 48 h and then transferred to the top of the Matrigel-coated invasion chambers in 1% fetal calf serum DMEM/F12 (2x104 cells/well). DMEM/F12 containing 10% fetal calf serum was added to the lower chambers. Following incubation for 24 h, cells that remained on the top of the filter were removed and cells that migrated to the lower surface were fixed in 90% alcohol followed by crystal violet staining. The values for invasion were obtained by counting three fields per membrane and represented as the average of six independent experiments made over multiple days.

Wound healing migration assay

When U2OS cells transfected with miR-195 or negative control oligonucleotides were grown to confluence, a scratch in the cell monolayer was made with a micropipette tip. Following incubation of the cells under standard conditions for 24 h, the plates were washed twice with fresh medium and images were captured at different times. The migration potential was estimated by counting the cells that migrated from the wound edge. The cell migration rate was obtained by counting three fields per area and represented as the average of six independent experiments made over multiple days.

Western blot analysis

U2OS cells in the exponential growth phase were transfected with miR-195 for 48 h. Total proteins were isolated from U2OS cells. Protein concentrations were measured using a Micro BCA protein assay kit (Pierce, Rockford, IL, USA). Proteins were resolved by 10% SDS-PAGE gel, transferred to the nitrocellulose membrane and blocked in 5% non-fat dry milk in Tris-buffered saline pH 7.4, containing 0.05% Tween-20. They were subsequently blotted with a rabbit polyclonal antibody against FASN (1:1000, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and goat anti-rabbit IgG (1:3000, Santa Cruz), with β-actin used as a loading control. Signals were detected by secondary antibodies labeled with horseradish peroxidase (HRP). All western blot analyses were performed six times.

Statistical analysis

Data were expressed as the means ± SD of at least three experiments. A one-way analysis of variance (ANOVA) test and a least significant difference (LSD) test were used for statistical analysis. A value of p<0.05 was considered to indicate a statistically significant result. All analyses were performed using SPSS version 13.0 (Statistical Package for the Social Sciences, Chicago, IL, USA).

Results

miR-195 inhibits cell invasion and migration in vitro

To further investigate the effect of miR-195 on U2OS cell invasion and migration, we employed the Transwell invasion assay and wound healing assay. U2OS cells were transfected with miR-195 or negative miRNA. We observed a significant inhibition of invasion into Matrigel in miR-195-transfected cells (Fig. 1A and B; P<0.05). We also noted that the number of migrated cells transfected with miR-195 was significantly fewer than the number transfected with negative miRNA (Fig. 2C and D; P<0.05). These results suggest that the upregulation of miR-195 inhibits the invasion and migration of U2OS cells.

FASN is a direct target of miR-195

To validate whether miR-195 regulates FASN directly through a putative binding site in U2OS cells, we cloned FASN 3′-UTR in the predicted miRNA binding site into the luciferase gene (pSiCHECK2; Promega). Following cotransfection with the pSiCHECK2 vectors and miR-195 or the negative control miRNA, the upregulation of miR-195 in U2OS cells transfected with miR-195 resulted in a significant decrease in the luciferase activity of the wild-type FASN 3′-UTR (Fig. 2; P<0.05). The results indicate that FASN is a direct target of miR-195.

miR-195 negatively regulates FASN expression in U2OS cells

To investigate the correlation between miR-195 and FASN, miR-195 was upregulated in U2OS cells by treatment with miR-195 for 36 h. The expression levels of FASN mRNA and protein were measured by qRT-PCR and western blot analysis. The data (2ΔΔCt = 0.162±0.01179) revealed that the FASN mRNA expression in cells transfected with the negative control vector was six-fold higher than the expression in the cells transfected with miR-195. Western blot analysis revealed that upregulated miR-195 in cells leads to a corresponding decrease in endogenous FASN protein (Fig. 3). These data suggest that miR-195 may negatively regulate FASN expression.

Discussion

miR-195, one of the miR-16/15/195/424/497 family members, has been shown to play an important role in tumorigenesis. Recently, miR-195 has been reported to be downregulated in hepatocellular carcinoma, adrenocortical carcinoma and squamous cell carcinoma of the tongue (2934). However, in chronic lymphocytic leukemia and breast cancer, miR-195 expression is reported to be upregulated (3539). Hence, the deregulation of miR-195 may be different in different types of cancer, and the role of miR-195 in carcinogenesis and progression cannot simply be concluded to be that of a tumor suppressor or an oncogene. The roles of miR-195 deregulation in cancer development remain to be further investigated. In the present study, we found that miR-195 is downregulated in the human OS cell line U2OS. The inhibition of migration and invasion due to the upregulation of miR-195 in the human OS cell line U2OS was also observed. This suggests that miR-195 functions as a tumor suppressor and inhibits U2OS cell migration and invasion, which is consistent with its roles in gastric cancer, colorectal cancer and hepatocellular carcinoma (27,29,40).

Our previous study reported that the inhibition of FASN causes a decrease in OS cell invasion and migration. The prediction of the FASN gene was performed using Targetscan software (microRNA.org and TargetScan.human6.0). This revealed that miR-195 may be targeting FASN. In the present study, RT-PCR and western blotting were performed to investigate the molecular mechanisms that inhibit the migration and invasion by restoring miR-195 in U2OS and to detect the expression levels of FASN mRNA and protein in U2OS cells. The results revealed that FASN expression was significantly inhibited in cells transfected with miR-195 when compared with the control group (Fig. 3). This suggests that the restoration of miR-195 expression may inhibit FASN expression in U2OS cells. Furthermore, to identify whether miR-195 can genuinely regulate the expression of FASN, the FASN 3′-UTR was cloned into the pSiCHECK2, placing the 3′-UTR with the majority of potential miRNA binding sites downstream of the coding sequence of luciferase (pMiR-Report; Promega). U2OS cells were cotransfected with the pSiCHECK2 vector containing the 3′-UTR and miR-195 or negative miRNA. We found that the overexpression of miR-195 significantly reduced the luciferase activity from the reporter construct containing the FASN 3′-UTR. This indicates that FASN is a direct miR-195 target. However, as there were hundreds of predicted targets of miR-195 revealed in the TargetScan prediction and a single miRNA has been proven to target multiple mRNAs in order to regulate gene expression (41), it is probable that other targets of miR-195 may also participate in OS migration and invasion and miR-195 may also target different molecules in different types of cancer. Additionally, the tumor microenvironment may influence tumor progression, invasion and migration. Therefore, further studies are needed to identify the entire role of miR-195 in OS metastasis.

Our present study indicated that the expression of the oncogene FASN is negatively regulated by miR-195 through a special binding site in the FASN 3′-UTR. Moreover, miR-195 inhibits cell invasion and migration in U2OS cells. These results suggest that miR-195 may serve as a target in the discovery of effective therapies for OS.

References

1. 

L MirabelloRJ TroisiSA SavageOsteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results ProgramCancer11515311543200910.1002/cncr.2412119197972

2. 

VO LewisWhat’s new in musculoskeletal oncologyJ Bone Joint Surg Am91154615562009

3. 

PA MeyersCL SchwartzM KrailoOsteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexateJ Clin Oncol2320042011200510.1200/JCO.2005.06.03115774791

4. 

Y ChoGH JungSH ChungJY KimY ChoiJD KimLong-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institutionClin Orthop Surg34854201121369478

5. 

H TsuchiyaK TomitaY MoriCaffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcomaAnticancer Res1865766619989584049

6. 

T BollingP SchullerB DistelmaierPerioperative high-dose rate brachytherapy using a bendy applicator (flab): treatment results of 74 patientsAnticancer Res2838853890200819192645

7. 

N MarinaM GebhardtL TeotR GorlickBiology and therapeutic advances for pediatric osteosarcomaOncologist9422441200410.1634/theoncologist.9-4-42215266096

8. 

T WadaK IsuN TakedaM UsuiS IshiiS YamawakiA preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factorOncology53221227199610.1159/000227564

9. 

CS YehJY WangTL ChengCH JuanCH WuSR LinFatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by Microarray-Bioinformatics analysisCancer Lett233297308200610.1016/j.canlet.2005.03.05015885896

10. 

D HessRA IgalGenistein downregulates de novo lipid synthesis and impairs cell proliferation in human lung cancer cellsExp Biol Med (Maywood)236707713201110.1258/ebm.2011.01026521565896

11. 

PL AloM AminiF PiroImmunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinomaAnticancer Res2725232527200717695548

12. 

K WalterSM HongS NyhanSerum fatty acid synthase as a marker of pancreatic neoplasiaCancer Epidemiol Biomarkers Prev1823802385200910.1158/1055-9965.EPI-09-014419723916

13. 

Y OkawaT HideshimaH IkedaFatty acid synthase is a novel therapeutic target in multiple myelomaBr J Haematol141659671200810.1111/j.1365-2141.2008.07114.x

14. 

T MigitaS RuizA FornariFatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancerJ Natl Cancer Inst101519532200910.1093/jnci/djp03019318631

15. 

H OritaJ CoulterE TullyFP KuhajdaE GabrielsonInhibiting fatty acid synthase for chemoprevention of chemically induced lung tumorsClin Cancer Res1424582464200810.1158/1078-0432.CCR-07-417718413838

16. 

DT ColemanR BigelowJA CardelliInhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradationMol Cancer Ther8214224200910.1158/1535-7163.MCT-08-072219139131

17. 

GE SaatiMC ArcherInhibition of fatty acid synthase and Sp1 expression by 3,3′-diindolylmethane in human breast cancer cellsNutr Cancer637907942011

18. 

M NotarnicolaS PisantiV TutinoEffects of olive oil polyphenols on fatty acid synthase gene expression and activity in human colorectal cancer cellsGenes Nutr66369201110.1007/s12263-010-0177-721437031

19. 

M NotarnicolaC MessaMG RefoloV TutinoA MiccolisMG CarusoPolyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell lineLipids Health Dis1010201110.1186/1476-511X-10-1021244676

20. 

KG ZecchinFA RossatoHF RaposoInhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosisLab Invest91232240201110.1038/labinvest.2010.15720805790

21. 

MA CarvalhoKG ZecchinF SeguinFatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma modelInt J Cancer12325572565200810.1002/ijc.2383518770866

22. 

S MurataK YanagisawaK FukunagaFatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in miceCancer Sci10118611865201010.1111/j.1349-7006.2010.01596.x20491775

23. 

VN KimJ HanMC SiomiBiogenesis of small RNAs in animalsNat Rev Mol Cell Biol10126139200910.1038/nrm263219165215

24. 

DP BartelMicroRNAs: target recognition and regulatory functionsCell136215233200910.1016/j.cell.2009.01.00219167326

25. 

MA Valencia-SanchezJ LiuGJ HannonR ParkerControl of translation and mRNA degradation by miRNAs and siRNAsGenes Dev20515524200610.1101/gad.139980616510870

26. 

GA CalinC SevignaniCD DumitruHuman microRNA genes are frequently located at fragile sites and genomic regions involved in cancersProc Natl Acad Sci USA10129993004200410.1073/pnas.030732310114973191

27. 

X WangJ WangH MaJ ZhangX ZhouDownregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancerMed Oncol201121390519

28. 

X BaiD MaA LiuRheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38Science318977980200710.1126/science.114737917991864

29. 

T XuY ZhuY XiongYY GeJP YunSM ZhuangMicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cellsHepatology50113121200910.1002/hep.2291919441017

30. 

PS SoonLJ TaconAJ GillmiR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancerClin Cancer Res1576847692200910.1158/1078-0432.CCR-09-158719996210

31. 

TS WongXB LiuBY WongRW NgAP YuenWI WeiMature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongueClin Cancer Res1425882592200810.1158/1078-0432.CCR-07-066618451220

32. 

L LiuL ChenY XuR LiX DumicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cellsBiochem Biophys Res Commun400236240201010.1016/j.bbrc.2010.08.04620727858

33. 

D LiY ZhaoC LiuAnalysis of MiR-195 and MiR-497 expression, regulation and role in breast cancerClin Cancer Res1717221730201110.1158/1078-0432.CCR-10-180021350001

34. 

B BrennerMB HoshenO PurimMicroRNAs as a potential prognostic factor in gastric cancerWorld J Gastroenterol1739763985201110.3748/wjg.v17.i35.397622046085

35. 

HM HeneghanN MillerR KellyJ NewellMJ KerinSystemic miR-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage diseaseOncologist15673682201010.1634/theoncologist.2010-010320576643

36. 

HM HeneghanN MillerAJ LoweryKJ SweeneyJ NewellMJ KerinCirculating microRNAs as novel minimally invasive biomarkers for breast cancerAnn Surg251499505201010.1097/SLA.0b013e3181cc939f20134314

37. 

BN HannafonP SebastianiA de las MorenasJ LuCL RosenbergExpression of microRNA and their gene targets are dysregulated in preinvasive breast cancerBreast Cancer Res13R24201110.1186/bcr283921375733

38. 

H ZhangSB SuQM ZhouYY LuDifferential expression profiles of microRNAs between breast cancer cells and mammary epithelial cellsAi Zheng28493499200919624877

39. 

DL ZanetteF RivadaviaGA MolfettamiRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemiaBraz J Med Biol Res4014351440200710.1590/S0100-879X200700110000317934639

40. 

WY WuXY XueZJ ChenPotentially predictive microRNAs of gastric cancer with metastasis to lymph nodeWorld J Gastroenterol1736453651201110.3748/wjg.v17.i31.364521987613

41. 

M SelbachB SchwanhausserN ThierfelderZ FangR KhaninN RajewskyWidespread changes in protein synthesis induced by microRNAsNature4555863200810.1038/nature0722818668040

Related Articles

Journal Cover

November 2012
Volume 4 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Mao, J.H., Zhou, R.P., Peng, A.F., Liu, Z.L., Huang, S.H., Long, X.H., & Shu, Y. (2012). microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. Oncology Letters, 4, 1125-1129. https://doi.org/10.3892/ol.2012.863
MLA
Mao, J. H., Zhou, R. P., Peng, A. F., Liu, Z. L., Huang, S. H., Long, X. H., Shu, Y."microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN". Oncology Letters 4.5 (2012): 1125-1129.
Chicago
Mao, J. H., Zhou, R. P., Peng, A. F., Liu, Z. L., Huang, S. H., Long, X. H., Shu, Y."microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN". Oncology Letters 4, no. 5 (2012): 1125-1129. https://doi.org/10.3892/ol.2012.863